These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2950730)

  • 1. Pharmacokinetics of L-dopa in patients with Parkinson's disease.
    Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG
    Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 3. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F
    MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].
    Lhermitte F; Agid Y; Feuerstein C; Serre F; Signoret JL; Studler JM; Bonnet AM
    Rev Neurol (Paris); 1977; 133(8-9):445-54. PubMed ID: 929037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: new treatments.
    Stewart RM
    Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C; Asper R; Baumgartner G
    Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of levodopa and motor fluctuations.
    Hardie RJ; Lees AJ; Stern GM
    Adv Neurol; 1987; 45():487-92. PubMed ID: 3825728
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.
    Hale MS; Bellizzi J
    J Nerv Ment Dis; 1980 May; 168(5):312-4. PubMed ID: 7365497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinsonism treated with levodopa: progression and mortality.
    Maier Hoehn MM
    J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1993; 60():181-5. PubMed ID: 8420133
    [No Abstract]   [Full Text] [Related]  

  • 20. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.